Vascular Disease clinical trials at UCSD

5 in progress, 2 open to eligible people

Showing trials for

  • IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

    open to eligible people ages 21 years and up

    The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

    San Diego, California and other locations

  • PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    open to eligible people ages 18-95

    A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

    La Jolla, California and other locations

  • Ralinepag to Improve Treatment Outcomes in PAH Patients

    Sorry, in progress, not accepting new patients

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

    La Jolla, California and other locations

  • Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

    Sorry, accepting new patients by invitation only

    Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

    La Jolla, California and other locations

  • Artificial Intelligence for Early Detection of Peripheral Artery Disease

    Sorry, not yet accepting patients

    The goal of this clinical trial is to test an AI-based screening tool that will help to identify patients at high risk of having undiagnosed peripheral artery disease. The primary outcome measure is overall rate of new PAD diagnoses. Secondary outcomes include rate of new secondary prevention measures initiated for PAD, which will include new prescriptions for antiplatelets, PAD-dosed rivaroxaban, statins, smoking cessation counseling or referrals, and/or supervised exercise therapy referrals also aggregated at a clinic and site level.

Our lead scientists for Vascular Disease research studies include .

Last updated: